Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 904-910

  Ribrag, Vincent ^a   Tilly, Hervé ^b   Casasnovas, Olivier ^c   Bosly, André ^d   Bouabdallah, Reda ^e   Delarue, Richard ^f   Boue, François ^g   Bron, Dominique ^h   Feugier, Pierre ⁱ   Haioun, Corinne ^j   Offner, Firtz ^k   Coiffier, Bertrand ^l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e INSTITUT PAOLI CALMETTES   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g HÔPITAL ANTOINE BÉCLÈRE   (France)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ CHU NANCY BRABOIS   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

Bortezomib; Clinical trial; Follicular lymphoma; Phase II; Salvage therapy

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HERPES ZOSTER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84873718393     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.015     Document Type: Article

References (14)

1. Anon A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project Blood 89 1997 3909 3918
2. T.D. Archuleta, and J.O. Armitage Advances in follicular lymphoma Semin Oncol 31 2004 66 71
3. W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, and M. Unterhalt Current management of follicular lymphomas Br J Haematol 136 2007 191 202
4. P. Solal-Céligny, P. Roy, and P. Colombat Follicular lymphoma international prognostic index Blood 104 2004 1258 1265
5. R.I. Fisher, M. LeBlanc, O.W. Press, D.G. Maloney, J.M. Unger, and T.P. Miller New treatment options have changed the survival of patients with follicular lymphoma J Clin Oncol 23 2005 8447 8452
6. W.T. Swenson, J.E. Wooldridge, C.F. Lynch, V.L. Forman-Hoffman, E. Chrischilles, and B.K. Link Improved survival of follicular lymphoma patients in the United States J Clin Oncol 23 2005 5019 5026
7. Q. Liu, L. Fayad, and F. Cabanillas Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center J Clin Oncol 24 2006 1582 1589
8. A. Goy, A. Younes, and P. McLaughlin Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 2005 667 675
9. O.A. O'Connor, J. Wright, and C. Moskowitz Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 2005 676 684
10. N. Di Bella, R. Taetle, and K. Kolibaba Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma Blood 115 2010 475 480
11. J. Gerecitano, C. Portlock, and C. Moskowitz Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Br J Haematol 146 2009 652 655
12. O.A. O'Connor, C. Portlock, and C. Moskowitz Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes Clin Cancer Res 16 2010 719 726
13. S.J. Strauss, L. Maharaj, and S. Hoare Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity J Clin Oncol 24 2006 2105 2112
14. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol 17 1999 1244 1253